Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02393573
Other study ID # 14-264-SDR
Secondary ID
Status Terminated
Phase N/A
First received February 10, 2015
Last updated March 21, 2018
Start date November 2015
Est. completion date March 2018

Study information

Verified date March 2018
Source McGill University Health Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Major surgery results in a stress- induced catabolic response, marked by post-operative insulin resistance, hyperglycemia and loss of body protein, which is associated with increased morbidity, mortality and adverse outcomes. There has been a great deal of research on different approaches to optimize post-operative insulin sensitivity including hormonal and nutritional interventions, minimally invasive surgical techniques and epidural anesthesia. However, the correlation between insulin resistance and body protein loss is not well understood. Metformin is the most widely used insulin sensitizing and blood glucose-lowering drug in treatment of type 2 diabetic patients. This study will: 1) estimate the correlation between insulin resistance and body protein loss in pre-diabetic lung/colorectal resection patients; 2) investigate whether the post-operative metabolic state can be improved by the pre-operative administration of metformin; and assess the impact of metformin on surgical complications and hospital length of stay. The results of this study will provide insight into the relationship between insulin resistance and post-operative adverse events and potentially suggest a novel approach to improve outcomes using Metformin, a drug already in wide clinical use.


Recruitment information / eligibility

Status Terminated
Enrollment 7
Est. completion date March 2018
Est. primary completion date March 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Elective open anatomic lung resections: segmentectomy, lobectomy, bi-lobectomy

2. Colorectal surgery for non-metastatic disease (including right, transverse, left, sigmoid, subtotal, total, and hemicolectomy)

3. Primary or secondary lung cancer

4. At least 18 years of age with

5. HbA1c 5.7- 6.5 %

6. Not receiving any kind of glucose lowering medication.

Exclusion Criteria:

1. Already diagnosed with diabetes (Hb A1c > 6.5%)

2. Are pre-diabetic receiving glucose lowering intervention ( any glucose lowering medication)

3. Have renal or liver dysfunction (serum creatinine above 124 micromol/L in women and 133 micromol/L in men, bilirubin >50 micromol/L)

4. will undergo extended resection of adjacent organs, chest wall resections, bronchoplasty, non-anatomic lung resections

5. Will undergo Pneumonectomy

6. Non-elective operations

7. Have mental conditions (e.g. dementia, disabling orthopedic and neuromuscular disease, psychosis),

8. Have cardiac abnormalities, severe end-organ disease such as cardiac failure (New York Heart Association classes III-IV), Chronic obstructive pulmonary disease(COPD), sepsis, morbid obesity (BMI >40 kg/m2), anemia (hematocrit < 30 %, hemoglobin <100g/L albumin < 25mg/dl)

9. Have received steroids for longer than 30 days

10. Have poor English or French comprehension.

Study Design


Intervention

Drug:
Metformin
Patients will take metformin for two weeks before Surgery and 2 days after the surgery
Placebo
Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery

Locations

Country Name City State
Canada Montreal General Hospital Montreal Quebec

Sponsors (3)

Lead Sponsor Collaborator
McGill University Health Center Medtronic - MITG, Mitacs

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in fasting blood glucose the level of plasma glucose after 6 hours of fasting 2 weeks before surgery (pre-operative) and on the morning before the surgery and every morning after the surgery (post operative) for three days or until discharge which ever comes earlier
Secondary Change in whole body protein balance The difference between the Pre-operative whole body protein balance( prior to metformin treatment) and the post operative whole body protein balance 2 weeks before surgery (pre-operative) and hours after the surgery (post operative)
Secondary Comparing the Homeostasis model assessment (HOMA) index at three different time points ( by employing Fasting blood sugar and Plasma Insulin) at 3 time points as follow : 2 weeks before surgery, on the day of surgery and 48 hours after the surgery
Secondary glycosylated Hba1c plasma level of glycosylated Hba1c 2 weeks before surgery
Secondary Comparing the pre-operative body impedance and the post operative body impedance (to asses the body composition specifically the amount of body fat) Measures body composition specifically fat content 2 weeks before surgery and 48 hours after the surgery
Secondary Surgical Complications Any complication related to the surgery with in 30 days post operation 30 days after operation
Secondary length of hospital stay Length of hospital stay is calculated as the total length of hospitalization from the date of admission for the purpose of surgery until the date of discharge from the hospital Up to 30 days after operation
See also
  Status Clinical Trial Phase
Completed NCT03142633 - MicroRNA as Biomarkers for Development of Metabolic Syndrome in Women With Polycystic Ovary Syndrome
Recruiting NCT04984226 - Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD Phase 2
Recruiting NCT05354245 - Using a Complex Carbohydrate Mixture to Steer Fermentation and Improve Metabolism in Adults With Overweight and Prediabetes (DISTAL) N/A
Completed NCT03383822 - Regulation of Endogenous Glucose Production by Brain Insulin Action in Insulin Resistance Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Suspended NCT03652987 - Endocrine and Menstrual Disturbances in Women With Polycystic Ovary Syndrome (PCOS)
Completed NCT04203238 - Potato Research for Enhancing Metabolic Outcomes N/A
Recruiting NCT03658564 - Preoperative Oral Carbohydrate Treatment Minimizes Insulin Resistance N/A
Completed NCT04183257 - Effect of Escalating Oral Vitamin D Replacement on HOMA-IR in Vitamin D Deficient Type 2 Diabetics Phase 4
Completed NCT04117802 - Effects of Maple Syrup on Gut Microbiota Diversity and Metabolic Syndrome N/A
Completed NCT03627104 - Effect of Dietary Protein and Energy Restriction in the Improvement of Insulin Resistance in Subjects With Obesity N/A
Completed NCT05124847 - TREating Pediatric Obesity N/A
Active, not recruiting NCT03288025 - Pulmonary Arterial Hypertension Improvement With Nutrition and Exercise (PHINE) N/A
Completed NCT03809182 - Effect of Dexmedetomidine on Postoperative Glucose and Insulin Levels. Phase 4
Completed NCT01809288 - Identifying Risk for Diabetes and Heart Disease in Women
Completed NCT04642482 - Synbiotic Therapy on Intestinal Microbiota and Insulin Resistance in Obesity Phase 4
Terminated NCT03278236 - Does Time Restricted Feeding Improve Glycaemic Control in Overweight Men? N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A
Not yet recruiting NCT05540249 - Pre-operative Carbohydrates in Diabetic Patients Undergoing CABG N/A
Withdrawn NCT04741204 - Metformin Use to Reduce Disparities in Newly Diagnosed Breast Cancer Phase 4